Sert, E. Et Al. 2018. Dramatic Reduction of LATS2 Tumor Suppressor Protein Expression in Patients with CLL: Evaluation of LATS2 Levels with Clinical Features and Immunophenotypic Profile. UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.28, no.3 , 137-146.

Sert, E., Coskunpinar, E., Yenerel, M. N., Aktan, M., Ozturk, D., Ozturk, O., ... Yilmaz-Aydogan, H.(2018). Dramatic Reduction of LATS2 Tumor Suppressor Protein Expression in Patients with CLL: Evaluation of LATS2 Levels with Clinical Features and Immunophenotypic Profile. UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.28, no.3, 137-146.

Sert, Esra Et Al. "Dramatic Reduction of LATS2 Tumor Suppressor Protein Expression in Patients with CLL: Evaluation of LATS2 Levels with Clinical Features and Immunophenotypic Profile," UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.28, no.3, 137-146, 2018

Sert, Esra Et Al. "Dramatic Reduction of LATS2 Tumor Suppressor Protein Expression in Patients with CLL: Evaluation of LATS2 Levels with Clinical Features and Immunophenotypic Profile." UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.28, no.3, pp.137-146, 2018

Sert, E. Et Al. (2018) . "Dramatic Reduction of LATS2 Tumor Suppressor Protein Expression in Patients with CLL: Evaluation of LATS2 Levels with Clinical Features and Immunophenotypic Profile." UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.28, no.3, pp.137-146.

@article{article, author={Esra SERT Et Al. }, title={Dramatic Reduction of LATS2 Tumor Suppressor Protein Expression in Patients with CLL: Evaluation of LATS2 Levels with Clinical Features and Immunophenotypic Profile}, journal={UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI}, year=2018, pages={137-146} }